ArticleEuropean journal of microbiology & immunology2025
CD47 monoclonal antibodies differ in their capacity to induce immune response.
Article in European journal of microbiology & immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mouse Integrin Associated Protein (MIAP) monoclonal antibodies are widely used for immunotherapeutic blockade of CD47. The anti-CD47 clones MIAP301 and MIAP410 have been studied as an immunotherapeutic treatment in the context of cancer and infectious diseases. To investigate the degree of induction of immune response afforded by these anti-CD47 clones, we treated C57BL/6 mice with MIAP301 or MIAP410, or isotype for two days and infected them with lymphocytic choriomeningitis virus (LCMV). We found that the treatment of MIAP301 led to a significant increase in mRNA expression of IFNα4 and IFNβ1 compared to MIAP410 or isotype. Our study further revealed that MIAP301 treatment enhanced the numbers of CD11b+ macrophages and CD11c+ dendritic cells, as well as improved phagocytic capacity. Analysis of NK and T cells showed a subtle difference, and a significantly increased IFN-γ+ NK cell in the mice treated with MIAP301. Both anti-CD47 antibodies significantly increased NK cells, CD8+, and CD4+ T cells quantity and quality when compared to isotype. Overall, our findings indicate that MIAP301 treatment significantly increases myeloid innate immune signaling compared to MIAP410 treatment. Considering the evolving preclinical studies using anti-CD47 for therapy, our study findings may be important when deciding which clone to use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.